POTS-FLOW: Interplay Between Gut Hormones and Autonomic Postprandial Blood Flow Regulation in Patients With POTS
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-50
SponsorUniversity of Copenhagen
About this trial
This study will describe the interplay between the gut hormones GIP and CCK and their regulation of blood flow to the large vessels in patients with Postural Orthostatic Tachycardia Syndrome (POTS) and GIP, CCK and GLP-1 in healthy. This is addressed by hormone infusions during MR-scans of the abdomen and intake of oral glucose.
Eligibility criteria
Qualifiers
Previously diagnosed with POTS in tilt test or active stand-test (either newly diagnosed within last 3 months or in new tilt test/active stand test during screenings visit)
Reproducible orthostatic intolerance with raise in HR on >30 bpm when standing within 10 minutes of change of supine to standing in age >19 years or >40 bpm in age 18-19 years.
POTS symptoms/orthostatic intolerance
Age 18-50
Disqualifiers
Chronic illness
Metallic implants
Above 10 alcoholic drinks or week or substance abuse
Other types of sinus tachycardia or heart disease
Trial design
Treatments tested in this trial
- Saline/Placebo
- GIPR antagonist
- GLP-1R antagonist
- CCK agonist
Treatment groups
30 Participants
are divided into 4 treatment groupsSponsors and collaborators
University of Copenhagen
Lead sponsor
Rigshospitalet, Denmark
Collaborator
Source ClinicalTrials.gov